시장보고서
상품코드
1994510

심혈관 유전자 검사 시장 보고서(2026년)

Cardiovascular Genetic Testing Global Market Report 2026

발행일: | 리서치사: 구분자 The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

심혈관 유전자 검사 시장 규모는 최근 급성장하고 있습니다. 2025년 39억 3,000만 달러에서 2026년에는 43억 5,000만 달러에 이르고, CAGR 10.8%로 성장할 전망입니다. 지난 수년간의 성장 요인으로는 유전성 심혈관 질환에 대한 인식 증가, 분자진단 기술의 발전, 유전자 시퀀싱 비용의 감소, 유전 상담 서비스 이용 확대, 심혈관 유전체학 연구의 활성화 등을 꼽을 수 있습니다.

심혈관 유전자 검사 시장 규모는 향후 몇 년간 급성장이 전망되고 있습니다. 2030년에는 66억 2,000만 달러에 이르고, CAGR은 11.0%를 나타낼 전망입니다. 예측 기간 동안의 성장은 정밀의료 접근법에 대한 수요 증가, 인구 기반 유전자 스크리닝의 확산, AI를 활용한 돌연변이 분석의 확대, 임상 의사결정에 유전체학의 통합 발전, 예방적 심혈관 의료에 대한 관심 증가에 기인하는 것으로 분석됩니다. 예측 기간의 주요 동향으로는 예측적 유전자 위험 평가의 보급, 다중 유전자 패널 검사의 활용 확대, 바이오인포매틱스와 AI 분석의 통합 발전, 약물유전체학 검사의 적용 확대, 개인 맞춤형 심혈관 케어에 대한 관심 증가 등을 꼽을 수 있습니다.

심혈관 질환의 유병률 증가는 향후 몇 년 동안 심혈관 유전자 검사 시장의 성장을 뒷받침할 것으로 예측됩니다. 심혈관질환(CVD)에는 심근경색, 뇌졸중, 고혈압 등 심장과 혈관에 영향을 미치는 다양한 질환이 포함됩니다. 심혈관질환 유병률 증가의 주요 요인은 도시화에 따른 좌식 생활습관이며, 이는 비만, 고혈압, 대사성 질환의 한 원인이 되고 있습니다. 심혈관 질환의 발생률이 증가함에 따라 심혈관 유전자 검사에 대한 수요가 증가하고 있습니다. 유전적 위험을 조기에 파악하면 심각한 심장 합병증 위험을 줄이기 위한 맞춤형 예방 전략과 표적 치료가 가능하기 때문입니다. 예를 들어, 미국 비영리단체인 미국심장협회(American Heart Association)에 따르면, 2024년 1월 기준 심혈관 질환으로 인한 연령 조정 사망률은 2024년 10만 명당 233.3명으로 2023년 10만 명당 224.4명보다 4.0% 증가할 것으로 예측했습니다. 4.0% 증가했습니다. 따라서 심혈관 질환의 유병률 증가가 심혈관 유전자 검사 시장의 성장에 기여하고 있습니다.

심혈관 유전자 검사 시장에서 사업을 전개하고 있는 주요 기업들은 의료적 필요성을 확보하고 환자별 병력에 따른 맞춤화를 실현하기 위해 의사가 의뢰하는 검사 등 혁신적인 솔루션 개발에 주력하고 있으며, 이를 통해 불필요한 검사와 그에 따른 비용을 절감하고 있습니다. 의사 지시형 검사란 의료진이 환자의 건강 상태를 평가, 모니터링 또는 관리의 지침으로 삼기 위해 의뢰하는 진단 절차를 말합니다. 예를 들어, 2025년 9월 미국 매사추세츠 종합병원 브리검(Mass General Brigham)은 브로드 클리니컬 랩(Broad Clinical Labs) 및 매사추세츠 종합병원 브리검 분자 의학 연구소(Mass General Brigham Laboratory for Molecular Medicine)와 제휴하여 Mass General Brigham Laboratory for Molecular Medicine)과 협력하여 8가지 심혈관 질환에 대한 유전적 위험을 평가하기 위한 유전자 검사를 시작했습니다. 심방세동, 관상동맥질환, 2형 당뇨병, 고지단백(a), 고콜레스테롤혈증, 고혈압, 흉부 대동맥류, 정맥혈전색전증 등의 질환에 대한 유전적 소인을 평가할 수 있는 검사로 자부담으로 제공되고 있습니다. 이번 검사 개발에는 미국 국립보건원(NIH)의 'All of Us' 연구 프로그램에 참여한 236,393명의 참가자의 유전형 및 임상 데이터를 활용했습니다. 공개된 다유전자 위험점수는 여러 구성요소 점수를 질병별 단일 종합적인 위험점수로 통합하는 탄성망 모델링 기법인 PRSmix를 사용하여 통합되었습니다. 고해상도 유전 데이터는 Broad Clinical Labs의 유전체-엑솜 혼합 분석을 통해 획득되며, CLIA 인증을 받은 Mass General Brigham Laboratory for Molecular Medicine에서 결과를 분석하여 환자들을 위한 알기 쉬운 보고서를 작성하고 있습니다.

자주 묻는 질문

  • 심혈관 유전자 검사 시장 규모는 어떻게 변화하고 있나요?
  • 심혈관 유전자 검사 시장의 성장 요인은 무엇인가요?
  • 심혈관 질환의 유병률 증가가 시장에 미치는 영향은 무엇인가요?
  • 심혈관 유전자 검사 시장에서 주요 기업들은 어떤 전략을 취하고 있나요?
  • 미국에서 심혈관 질환에 대한 유전자 검사는 어떻게 진행되고 있나요?

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 시장에서 주목 받는 신생 기업

제40장 주요 인수합병(M&A)

제41장 시장 잠재력이 높은 국가, 부문, 전략

제42장 부록

LSH

Cardiovascular genetic testing involves examining an individual's DNA to detect inherited genetic variants that elevate the likelihood of developing diseases of the heart and blood vessels, supporting early identification, individualized treatment decisions, and focused preventive measures. It allows healthcare professionals to estimate disease risk, inform medication choices, evaluate hereditary predisposition, and facilitate proactive cardiovascular care through precision-based medical strategies.

The primary testing types of cardiovascular genetic testing include predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and other testing categories. Predictive testing consists of genetic assessments that evaluate an individual's likelihood of developing cardiovascular disorders prior to symptom onset. These tests are applied to diseases such as inherited cardiomyopathies, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmias, aortopathies, and other related conditions. The technologies involved include cytogenetic testing, biochemical testing, and molecular testing. The applications cover chromosome analysis, genetic disease identification, cardiovascular disease diagnosis, and other uses, while the end users include hospitals and clinics, diagnostic laboratories, research organizations, genetic counseling centers, pharmaceutical companies, and direct-to-consumer testing providers.

Tariffs are impacting the cardiovascular genetic testing market by increasing costs of imported sequencing instruments, reagents, bioinformatics hardware, and advanced laboratory equipment. Diagnostic laboratories and research institutions in North America and Europe are most affected due to reliance on imported genomic technologies, while Asia-Pacific faces higher costs for test kit manufacturing and distribution. These tariffs are increasing testing expenses and slowing laboratory expansion. However, they are also encouraging domestic reagent production, localized sequencing infrastructure, and regional bioinformatics platform development that strengthen long-term testing capacity.

The cardiovascular genetic testing market research report is one of a series of new reports from The Business Research Company that provides cardiovascular genetic testing market statistics, including cardiovascular genetic testing industry global market size, regional shares, competitors with a cardiovascular genetic testing market share, detailed cardiovascular genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular genetic testing industry. This cardiovascular genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiovascular genetic testing market size has grown rapidly in recent years. It will grow from $3.93 billion in 2025 to $4.35 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to increasing awareness of inherited cardiovascular disorders, expansion of molecular diagnostic capabilities, declining costs of genetic sequencing, growing use of genetic counseling services, increased research in cardiovascular genomics.

The cardiovascular genetic testing market size is expected to see rapid growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to increasing demand for precision medicine approaches, rising adoption of population-based genetic screening, expansion of AI-driven variant interpretation, growing integration of genomics in clinical decision making, increasing focus on preventive cardiovascular healthcare. Major trends in the forecast period include increasing adoption of predictive genetic risk assessment, rising use of multigene panel testing, growing integration of bioinformatics and AI analytics, expansion of pharmacogenomic testing applications, enhanced focus on personalized cardiovascular care.

The rising prevalence of cardiovascular diseases is projected to support the growth of the cardiovascular genetic testing market in the coming years. Cardiovascular diseases (CVDs) include a range of disorders affecting the heart and blood vessels, such as heart attacks, strokes, and hypertension. The prevalence of cardiovascular diseases is increasing largely due to sedentary lifestyles linked to urbanization, which contribute to obesity, high blood pressure, and metabolic conditions. The growing incidence of cardiovascular diseases increases demand for cardiovascular genetic testing, as early identification of genetic risks enables personalized prevention strategies and targeted treatments to reduce the risk of severe heart complications. For example, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, representing a 4.0% increase from 224.4 per 100,000 in 2023. Therefore, the rising prevalence of cardiovascular diseases is contributing to the growth of the cardiovascular genetic testing market.

Leading companies operating in the cardiovascular genetic testing market are concentrating on developing innovative solutions, such as clinician-ordered tests, to ensure medical necessity and customization based on patient-specific conditions, reducing unnecessary testing and associated costs. A clinician-ordered test is a diagnostic procedure requested by a healthcare professional to assess, monitor, or guide the management of a patient's health condition. For instance, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in partnership with Broad Clinical Labs and the Mass General Brigham Laboratory for Molecular Medicine, launched a genetic test evaluating inherited risk for eight cardiovascular conditions. The clinician-ordered test is offered on a self-pay basis and assesses genetic predisposition to conditions such as atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its development utilized genotype and clinical data from 236,393 participants in the NIH's All of Us Research Program. Publicly available polygenic risk scores were integrated using PRSmix, an elastic-net modeling approach combining multiple component scores into a single comprehensive risk score per disease. High-resolution genetic data is captured through a blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine interprets results and generates patient-friendly reports.

In February 2025, Tempus AI Inc., a US-based precision medicine company, acquired Ambry Genetics for an undisclosed amount. This acquisition strengthens Tempus AI's strategy of combining diagnostics and data-driven insights to fuel innovation, enhancing its ability to deliver advanced solutions to healthcare providers, patients, and life sciences organizations. Ambry Genetics Corporation is a US-based company focused on cardiovascular genetic testing services.

Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.

North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cardiovascular genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiovascular genetic testing market includes revenues earned by entities through genetic testing services, genetic screening services, molecular diagnostic services, genomic sequencing services, variant interpretation services, bioinformatics analysis services, genetic counseling services, and personalized risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiovascular Genetic Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cardiovascular genetic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiovascular genetic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiovascular genetic testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types
  • 2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases
  • 3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing
  • 4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications
  • 5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing
  • Subsegments:
  • 1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing
  • 2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing
  • 3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing
  • 4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing
  • 5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing
  • 6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing
  • Companies Mentioned: Labcorp Holdings Inc.; Quest Diagnostics Inc.; ICON plc; Illumina Inc.; Apollo Hospitals; OPKO Health Inc.; Revvity Inc.; ARUP Laboratories Inc.; Mayo Clinic Laboratories; Fulgent Genetics Inc.; MedGenome Inc.; Genome Medical; PreventionGenetics; Eurofins Genomics LLC; Blueprint Genetics Inc.; MapmyGenome; GENinCode; Allelica Srl; Rocket Pharma Inc.; and Health in Code SL.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Cardiovascular Genetic Testing Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Cardiovascular Genetic Testing Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Cardiovascular Genetic Testing Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Cardiovascular Genetic Testing Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Artificial Intelligence & Autonomous Intelligence
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Predictive Genetic Risk Assessment
    • 4.2.2 Rising Use Of Multigene Panel Testing
    • 4.2.3 Growing Integration Of Bioinformatics And AI Analytics
    • 4.2.4 Expansion Of Pharmacogenomic Testing Applications
    • 4.2.5 Enhanced Focus On Personalized Cardiovascular Care

5. Cardiovascular Genetic Testing Market Analysis Of End Use Industries

  • 5.1 Hospitals And Clinics
  • 5.2 Diagnostic Laboratories
  • 5.3 Research Institutions
  • 5.4 Genetic Counseling Centers
  • 5.5 Pharmaceutical Companies

6. Cardiovascular Genetic Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Cardiovascular Genetic Testing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Cardiovascular Genetic Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Cardiovascular Genetic Testing Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Cardiovascular Genetic Testing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Cardiovascular Genetic Testing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Cardiovascular Genetic Testing Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Cardiovascular Genetic Testing Market Segmentation

  • 9.1. Global Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Predictive Testing, Carrier Testing, Prenatal And Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Other Testing Types
  • 9.2. Global Cardiovascular Genetic Testing Market, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Inherited Cardiomyopathies, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmia, Aortopathies, Other Diseases
  • 9.3. Global Cardiovascular Genetic Testing Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cytogenetic Testing, Biochemical Testing, Molecular Testing
  • 9.4. Global Cardiovascular Genetic Testing Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Other Applications
  • 9.5. Global Cardiovascular Genetic Testing Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals And Clinics, Diagnostic Laboratories, Research Institutions, Genetic Counseling Centers, Pharmaceutical Companies, Direct-To-Consumer Testing
  • 9.6. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Predictive Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Presymptomatic Risk Assessment, Familial Variant Screening, Polygenic Risk Evaluation, Late Onset Disease Prediction, Susceptibility Gene Testing
  • 9.7. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Carrier Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Autosomal Recessive Carrier Screening, Linked Carrier Screening, Expanded Carrier Screening Panels, Single Gene Carrier Screening, Family History Based Carrier Testing
  • 9.8. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Prenatal And Newborn Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Non Invasive Prenatal Genetic Testing, Invasive Prenatal Diagnostic Testing, Newborn Metabolic Screening, Congenital Heart Disease Genetic Screening, Neonatal Gene Panel Testing
  • 9.9. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Diagnostic Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Single Gene Diagnostic Testing, Multigene Panel Diagnostic Testing, Whole Exome Diagnostic Testing, Whole Genome Diagnostic Testing, Variant Confirmation Testing
  • 9.10. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Pharmacogenomic Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Drug Response Gene Testing, Adverse Drug Reaction Risk Testing, Dose Optimization Genetic Testing, Anticoagulant Response Testing, Cardiovascular Drug Metabolism Testing
  • 9.11. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Other Testing Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cascade Family Testing, Population Based Genetic Screening, Research Use Genetic Testing, Confirmatory Follow Up Testing, Clinical Trial Genetic Testing

10. Cardiovascular Genetic Testing Market Regional And Country Analysis

  • 10.1. Global Cardiovascular Genetic Testing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Cardiovascular Genetic Testing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Cardiovascular Genetic Testing Market

  • 11.1. Asia-Pacific Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Cardiovascular Genetic Testing Market

  • 12.1. China Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Cardiovascular Genetic Testing Market

  • 13.1. India Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Cardiovascular Genetic Testing Market

  • 14.1. Japan Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Cardiovascular Genetic Testing Market

  • 15.1. Australia Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Cardiovascular Genetic Testing Market

  • 16.1. Indonesia Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Cardiovascular Genetic Testing Market

  • 17.1. South Korea Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Cardiovascular Genetic Testing Market

  • 18.1. Taiwan Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Cardiovascular Genetic Testing Market

  • 19.1. South East Asia Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Cardiovascular Genetic Testing Market

  • 20.1. Western Europe Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Cardiovascular Genetic Testing Market

  • 21.1. UK Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Cardiovascular Genetic Testing Market

  • 22.1. Germany Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Cardiovascular Genetic Testing Market

  • 23.1. France Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Cardiovascular Genetic Testing Market

  • 24.1. Italy Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Cardiovascular Genetic Testing Market

  • 25.1. Spain Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Cardiovascular Genetic Testing Market

  • 26.1. Eastern Europe Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Cardiovascular Genetic Testing Market

  • 27.1. Russia Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Cardiovascular Genetic Testing Market

  • 28.1. North America Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Cardiovascular Genetic Testing Market

  • 29.1. USA Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Cardiovascular Genetic Testing Market

  • 30.1. Canada Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Cardiovascular Genetic Testing Market

  • 31.1. South America Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Cardiovascular Genetic Testing Market

  • 32.1. Brazil Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Cardiovascular Genetic Testing Market

  • 33.1. Middle East Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Cardiovascular Genetic Testing Market

  • 34.1. Africa Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Cardiovascular Genetic Testing Market Regulatory and Investment Landscape

36. Cardiovascular Genetic Testing Market Competitive Landscape And Company Profiles

  • 36.1. Cardiovascular Genetic Testing Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Cardiovascular Genetic Testing Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Cardiovascular Genetic Testing Market Company Profiles
    • 36.3.1. Labcorp Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Quest Diagnostics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. ICON plc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Apollo Hospitals Overview, Products and Services, Strategy and Financial Analysis

37. Cardiovascular Genetic Testing Market Other Major And Innovative Companies

  • OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., Health in Code SL

38. Global Cardiovascular Genetic Testing Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Cardiovascular Genetic Testing Market

41. Cardiovascular Genetic Testing Market High Potential Countries, Segments and Strategies

  • 41.1 Cardiovascular Genetic Testing Market In 2030 - Countries Offering Most New Opportunities
  • 41.2 Cardiovascular Genetic Testing Market In 2030 - Segments Offering Most New Opportunities
  • 41.3 Cardiovascular Genetic Testing Market In 2030 - Growth Strategies
    • 41.3.1 Market Trend Based Strategies
    • 41.3.2 Competitor Strategies

42. Appendix

  • 42.1. Abbreviations
  • 42.2. Currencies
  • 42.3. Historic And Forecast Inflation Rates
  • 42.4. Research Inquiries
  • 42.5. The Business Research Company
  • 42.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제